Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.94 USD | -1.02% | -2.51% | -2.02% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.02% | 158M | C | ||
-2.31% | 103B | B+ | ||
+0.56% | 95.28B | B+ | ||
+0.73% | 22.15B | B | ||
-17.37% | 21.02B | B+ | ||
-8.42% | 18.15B | A- | ||
-41.01% | 16.73B | A- | ||
-14.85% | 16.05B | B | ||
+3.21% | 13.68B | C+ | ||
+33.54% | 12.17B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PRQR Stock
- Ratings ProQR Therapeutics N.V.